Borgeson Blake sold $110K of RXRX
Borgeson Blake sold 30,000 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.68 ($0.11M total) on 2026-06-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Traders may monitor for follow-on insider activity, but the 10b5-1 structure generally reduces the predictive value for near-term price direction.
Market read
A specific insider sale datapoint for RXRX, with limited fundamental implications due to 10b5-1 pre-arrangement.
What to watch
The filing does not reveal whether other insiders bought/sold around the same time, nor does it indicate changes to the broader insider trading program.
Background
SEC Form 4 reports insider transactions; this director sale was executed under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Recursion Pharmaceuticals disclosed an insider director open-market sale of 30,000 shares at $3.6800 on June 2 under a 10b5-1 plan.
Low near-term impact; any reaction is likely muted unless followed by additional insider activity or fundamental catalysts.
Form 4 provides a specific transaction datapoint (size, price, date) but does not indicate new company fundamentals; 10b5-1 reduces interpretability as discretionary bearishness.
Market effects
Minimal—single-company insider Form 4 with 10b5-1 typically does not reset sector expectations.
None expected beyond RXRX-specific sentiment.
None expected.
Counterpoint
Even with 10b5-1, repeated or unusually large insider sales can coincide with perceived valuation risk and may still influence short-term sentiment.
Key entities
- issuerRecursion Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction disclosure (RXRX).
- insiderBorgeson Blake
Director who sold 30,000 shares at $3.6800 on June 2 under a 10b5-1 plan.
